BE granted SPC for Galliprant® on September 5, 2025. The SPC extends the period of exclusive sales rights for Galliprant® until March 1, 2031. This grant in BE marks the 10th country in Europe, following Italy, Holland, Spain, Germany, France, Ireland, Greece, Poland, and Great Britain, and a five-year extension has been granted to all 10 countries where we applied for the extension within Europe.

Galliprant®
Galliprant® (grapiprant tablets) is an EP4 receptor antagonist for the control of pain and inflammation associated with osteoarthritis in dogs. Elanco Animal Health Inc. is currently marketing Galliprant® in 30 countries including the US, Europe and Japan.

Supplementary Protection Certificate (SPC)
In major countries, a patent will expire 20 years after the filing date of the application. The patent exclusivity periods for pharmaceuticals may be extended for a maximum of five years to compensate for compulsory long time of development and regulatory approval.